Blair William & Co. IL Raises Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Blair William & Co. IL lifted its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 25.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,531 shares of the specialty pharmaceutical company’s stock after buying an additional 509 shares during the period. Blair William & Co. IL’s holdings in Jazz Pharmaceuticals were worth $312,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. CIBC Asset Management Inc boosted its holdings in Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 97 shares during the last quarter. UMB Bank n.a. lifted its position in shares of Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after purchasing an additional 130 shares during the last quarter. Waterfront Wealth Inc. grew its position in Jazz Pharmaceuticals by 1.4% in the 4th quarter. Waterfront Wealth Inc. now owns 9,675 shares of the specialty pharmaceutical company’s stock worth $1,191,000 after purchasing an additional 137 shares in the last quarter. Finally, Ellsworth Advisors LLC increased its stake in Jazz Pharmaceuticals by 0.4% in the 4th quarter. Ellsworth Advisors LLC now owns 37,962 shares of the specialty pharmaceutical company’s stock valued at $4,675,000 after buying an additional 149 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the sale, the chief executive officer now directly owns 439,744 shares of the company’s stock, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Patricia Carr sold 4,813 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.42, for a total transaction of $695,093.46. Following the completion of the transaction, the chief accounting officer now directly owns 8,237 shares of the company’s stock, valued at approximately $1,189,587.54. This represents a 36.88 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,736 shares of company stock valued at $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Barclays reaffirmed an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Needham & Company LLC reiterated a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Morgan Stanley restated an “overweight” rating and set a $183.00 price target (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Finally, Cantor Fitzgerald cut shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and boosted their target price for the company from $140.00 to $150.00 in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $187.71.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $110.04 on Friday. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The stock’s 50-day simple moving average is $132.27 and its 200 day simple moving average is $122.99. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market capitalization of $6.68 billion, a price-to-earnings ratio of 15.50, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.